SCHEMBL2712958

SCHEMBL2712958

CON(C)C(=O)c1cccc(OCC(F)(F)F)n1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.42
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
MLYCD O95822 1/20 0.38
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
SCN9A Q15858 3/20 0.36
FFAR4 Q5NUL3 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
HCRTR1 O43613 5/20 0.35
HCRTR2 O43614 5/20 0.35
UGCG Q16739 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16731953 0.84 SCN9A (0.51) L3MBTL1SCN9AUGCGPOLBMAPK1
SCHEMBL28404720 0.83 MAPK8 (0.48) CNR2MAPTKCNK3KCNK9TRPM8
SCHEMBL28937807 0.82 MLYCD (0.40) CNR2MAPTMLYCDKCNK3KCNK9
SCHEMBL30124835 0.82 MLYCD (0.40) CNR2MAPTMLYCDKCNK3KCNK9
SCHEMBL2717270 0.81 MAPT (0.59) CNR2MAPTL3MBTL1KCNK3KCNK9
SCHEMBL2714731 0.80 CNR2 (0.47) CNR2MAPTL3MBTL1KCNK3KCNK9
SCHEMBL28890156 0.80 HTR7 (0.54) POLB
SCHEMBL31191212 0.80 CNR2 (0.37) CNR2L3MBTL1MLYCDSCN9AHCRTR1
SCHEMBL30342225 0.80 L3MBTL1 (0.43) CNR2MAPTL3MBTL1MLYCDSCN9A
SCHEMBL29005252 0.80 L3MBTL1 (0.43) CNR2MAPTL3MBTL1MLYCDSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106478497-B Arylamine derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 CN disclosed
CN-111108092-A Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-05-05 CN disclosed
EP-2630122-B1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2016-11-30 EP disclosed
US-9302991-B2 Arylamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2016-04-05 US disclosed
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2014-11-13 US disclosed
EP-2630122-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc (JP) 2013-08-28 EP disclosed
WO-2012053186-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336377-A1 ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN2B, SCN1B, SCN2A CNR2 360/4885MAPT 3185/4885L3MBTL1 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.